Labiotech.eu

News and Trends 26 Jul 2022

Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens

Finnish immunotherapy company Valo Therapeutics Oy (ValoTx) has obtained exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. Valo said the deal will enable the rapid […]

July 26, 2022 - 2 minutesmins - By Jim Cornall

In Depth 26 Jul 2022

How DNA sequencing can safeguard against biodiversity loss

Preserving Earth’s biodiversity is crucial as we rely on healthy ecosystems for many services, from clean air and water to protection from floods and pandemics. DNA sequencing is an invaluable tool for characterizing biodiversity and informing conservation efforts. In Earth’s history, there have been five major mass extinction events — the most recent of which […]

July 26, 2022 - 8 minutesmins - By Omnia Ibrahim

News and Trends 26 Jul 2022

Ginkgo acquires Zymergen for $300M and picks up Bayer facility for $83M

U.S. cell programming company Ginkgo Bioworks has signed definitive agreements to acquire two teams and technologies. The deals are with Bayer and Zymergen. Bayer transaction The company confirmed the previously announced transaction with Bayer to expand Ginkgo’s platform capabilities in agricultural biologicals. Ginkgo will acquire Bayer’s 175,000-square-foot West Sacramento Biologics Research & Development site, team, […]

July 26, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 25 Jul 2022

Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization

The Committee for Medical Products for Human Use (CHMP) has recommended the European Commission (EC) make a marketing authorization under exceptional circumstances for a drug to treat a rare condition characterized by brain dysfunction. The drug is called NULIBRY (fosdenopterin) for injection therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. […]

July 25, 2022 - 4 minutesmins - By Liza Laws

News and Trends 25 Jul 2022

Bavarian Nordic gets European monkeypox approval for smallpox vaccine

Danish company Bavarian Nordic A/S says the European Commission (EC) has extended the marketing authorization for the company’s smallpox vaccine, IMVANEX, to include protection from monkeypox and disease caused by vaccinia virus. The approval, which follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) on July 22, 2022, is valid […]

July 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Jul 2022

Drug for acute treatment of social anxiety disorder did not meet primary endpoint

A nasal spray to treat anxiety did not meet its primary endpoint and was not significantly better than the placebo given during a phase 3 clinical trial. Vistagen Therapeutics Inc’s drug, PH94B, was designed to treat people living with anxiety, depression and other central nervous system (CNS) disorders announced the topline results on Friday (July […]

July 25, 2022 - 4 minutesmins - By Liza Laws

News and Trends 25 Jul 2022

NEOsphere Biotechnologies closes financing round

NEOsphere Biotechnologies GmbH has completed a series A financing round to expand its proteomics platform, which screens extensive small-molecule libraries for degraders of pathogenic proteins previously considered undruggable. The funding amount was not disclosed, however, the company told us there were four investors, with the main amount coming from Munich-based Ventura BioMed Investors GmbH. NEOSphere […]

July 25, 2022 - 3 minutesmins - By Jim Cornall

Daniel Baptista-Hon Faculty of Medicine M.U.S.T. Macao

News and Trends 25 Jul 2022

Macao university research finds mRNA vaccine booster offers more protection against Omicron variants

A study in Macao has found people taking the BioNTech mRNA vaccine as the third booster dose produce more neutralizing antibodies against Omicron variants. The study, led by Daniel Baptista-Hon, assistant professor at the Faculty of Medicine at the Macau University of Science and Technology (M.U.S.T.), and Ligong Lu, director of Zhuhai People’s Hospital, was […]

July 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Jul 2022

Replay launches with $55M to reprogram biology by writing and delivering big DNA

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, has launched with $55 million in seed financing. The round was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial. Replay, which is based in San Diego, Cal., and London, U.K., […]

July 25, 2022 - 3 minutesmins - By Jim Cornall

sano genetics trial recruitment precision medicine

Opinion 25 Jul 2022

How to improve patient recruitment in your precision medicine research

Precision medicine research relies on genetic testing at scale, but has long suffered recruitment and retention headaches. The answer, says Patrick Short, CEO of Sano Genetics, is to start early and engage participants deeply. I witnessed first-hand the power of national scale genomics research through my PhD work analyzing genome sequence data from more than […]

July 25, 2022 - 7 minutesmins - By External Contributor

lupus autoimmune disease neutrophil citryll

News and Trends 22 Jul 2022

Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis

British Columbia-based Aurinia Pharmaceuticals Inc. announced today (July 22) that its voclosporin drug has been recommended for marketing authorization to treat adults with active lupus nephritis (LN). The Canadian biopharma company said it is committed to delivering therapeutics that change the course of autoimmune disease after the Committee for Medicinal Products for Human Use (CHMP) […]

July 22, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed

London-based Freeline Therapeutics Holdings plc has just announced that positive data on treating haemophilia has been published by the New England Journal of Medicine (NEJM). This expands upon previous data for up to three-and-a-half years from the phase 1/2 dose-finding B-AMAZE of the company’s AAVS3 gene therapy candidate, FLT180a for people with the debilitating, hereditary […]

July 22, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens

How DNA sequencing can safeguard against biodiversity loss

Ginkgo acquires Zymergen for $300M and picks up Bayer facility for $83M

Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization

Bavarian Nordic gets European monkeypox approval for smallpox vaccine

Drug for acute treatment of social anxiety disorder did not meet primary endpoint

NEOsphere Biotechnologies closes financing round

Macao university research finds mRNA vaccine booster offers more protection against Omicron variants

Replay launches with $55M to reprogram biology by writing and delivering big DNA

How to improve patient recruitment in your precision medicine research

Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis

People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!